{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T15:37:18Z","timestamp":1793288238311,"version":"4.5.0"},"reference-count":115,"publisher":"American Medical Association (AMA)","issue":"18","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2023,5,9]]},"abstract":"<jats:sec id=\"ab-jrv230009-1\">\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>Cirrhosis affects approximately 2.2 million adults in the US. From 2010 to 2021, the annual age-adjusted mortality of cirrhosis increased from 14.9 per 100\u202f000 to 21.9 per 100\u202f000 people.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-jrv230009-2\">\n                    <jats:title>Observations<\/jats:title>\n                    <jats:p>The most common causes of cirrhosis in the US, which can overlap, include alcohol use disorder (approximately 45% of all cases of cirrhosis), nonalcoholic fatty liver disease (26%), and hepatitis C (41%). Patients with cirrhosis experience symptoms including muscle cramps (approximately 64% prevalence), pruritus (39%), poor-quality sleep (63%), and sexual dysfunction (53%). Cirrhosis can be diagnosed by liver biopsy but may also be diagnosed noninvasively. Elastography, a noninvasive assessment of liver stiffness measured in kilopascals, can typically confirm cirrhosis at levels of 15 kPa or greater. Approximately 40% of people with cirrhosis are diagnosed when they present with complications such as hepatic encephalopathy or ascites. The median survival time following onset of hepatic encephalopathy and ascites is 0.92 and 1.1 years, respectively. Among people with ascites, the annual incidence of spontaneous bacterial peritonitis is 11% and of hepatorenal syndrome is 8%; the latter is associated with a median survival of less than 2 weeks. Approximately 1% to 4% of patients with cirrhosis develop hepatocellular carcinoma each year, which is associated with a 5-year survival of approximately 20%. In a 3-year randomized clinical trial of 201 patients with portal hypertension, nonselective \u03b2-blockers (carvedilol or propranolol) reduced the risk of decompensation or death compared with placebo (16% vs 27%). Compared with sequential initiation, combination aldosterone antagonist and loop diuretics were more likely to resolve ascites (76% vs 56%) with lower rates of hyperkalemia (4% vs 18%). In meta-analyses of randomized trials, lactulose was associated with reduced mortality relative to placebo (8.5% vs 14%) in randomized trials involving 705 patients and reduced risk of recurrent overt hepatic encephalopathy (25.5% vs 46.8%) in randomized trials involving 1415 patients. In a randomized clinical trial of 300 patients, terlipressin improved the rate of reversal of hepatorenal syndrome from 39% to 18%. Trials addressing symptoms of cirrhosis have demonstrated efficacy for hydroxyzine in improving sleep dysfunction, pickle brine and taurine for reducing muscle cramps, and tadalafil for improving sexual dysfunction in men.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-jrv230009-3\">\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>Approximately 2.2 million US adults have cirrhosis. Many symptoms, such as muscle cramps, poor-quality sleep, pruritus, and sexual dysfunction, are common and treatable. First-line therapies include carvedilol or propranolol to prevent variceal bleeding, lactulose for hepatic encephalopathy, combination aldosterone antagonists and loop diuretics for ascites, and terlipressin for hepatorenal syndrome.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jama.2023.5997","type":"journal-article","created":{"date-parts":[[2023,5,9]],"date-time":"2023-05-09T18:30:38Z","timestamp":1683657038000},"page":"1589","source":"Crossref","is-referenced-by-count":406,"title":["Diagnosis and Management of Cirrhosis and Its Complications"],"prefix":"10.1001","volume":"329","author":[{"given":"Elliot B.","family":"Tapper","sequence":"first","affiliation":[{"name":"Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neehar D.","family":"Parikh","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"3","key":"jrv230009r1","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/S2468-1253(19)30349-8","article-title":"The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017.","volume":"5","author":"Sepanlou","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"jrv230009r2","doi-asserted-by":"publisher","first-page":"k2817","DOI":"10.1136\/bmj.k2817","article-title":"Mortality due to cirrhosis and liver cancer in the United States, 1999-2016.","volume":"362","author":"Tapper","year":"2018","journal-title":"BMJ"},{"issue":"2","key":"jrv230009r4","doi-asserted-by":"publisher","first-page":"294","DOI":"10.14309\/ajg.0000000000002011","article-title":"Patterns of care utilization and hepatocellular carcinoma surveillance.","volume":"118","author":"Serper","year":"2023","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"jrv230009r5","doi-asserted-by":"publisher","first-page":"3330","DOI":"10.1002\/hep.32032","article-title":"NAFLD and alcohol-associated liver disease will be responsible for almost all new diagnoses of cirrhosis in Canada by 2040.","volume":"74","author":"Flemming","year":"2021","journal-title":"Hepatology"},{"issue":"20","key":"jrv230009r6","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1001\/jama.2021.19569","article-title":"Association of bariatric surgery with major adverse liver and cardiovascular outcomes in patients with biopsy-proven nonalcoholic steatohepatitis.","volume":"326","author":"Aminian","year":"2021","journal-title":"JAMA"},{"issue":"24","key":"jrv230009r7","doi-asserted-by":"publisher","first-page":"2584","DOI":"10.1001\/jama.2012.144878","article-title":"Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis.","volume":"308","author":"van der Meer","year":"2012","journal-title":"JAMA"},{"issue":"15","key":"jrv230009r8","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1056\/NEJMoa033364","article-title":"Lamivudine for patients with chronic hepatitis B and advanced liver disease.","volume":"351","author":"Liaw","year":"2004","journal-title":"N Engl J Med"},{"issue":"12","key":"jrv230009r9","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1007\/s002770100371","article-title":"Clinically overt hereditary hemochromatosis in Denmark 1948-1985.","volume":"80","author":"Milman","year":"2001","journal-title":"Ann Hematol"},{"issue":"3","key":"jrv230009r10","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1016\/S0016-5085(97)70183-5","article-title":"Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis.","volume":"113","author":"Poupon","year":"1997","journal-title":"Gastroenterology"},{"issue":"1","key":"jrv230009r11","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.jhep.2010.01.037","article-title":"Treatment options for autoimmune hepatitis: a systematic review of randomized controlled trials.","volume":"53","author":"Lamers","year":"2010","journal-title":"J Hepatol"},{"issue":"4","key":"jrv230009r12","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1111\/hepr.2014.44.issue-4","article-title":"Effect of abstinence from alcohol on survival of patients with alcoholic cirrhosis: a systematic review and meta-analysis.","volume":"44","author":"Xie","year":"2014","journal-title":"Hepatol Res"},{"issue":"12","key":"jrv230009r13","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1056\/NEJMoa0907893","article-title":"Rifaximin treatment in hepatic encephalopathy.","volume":"362","author":"Bass","year":"2010","journal-title":"N Engl J Med"},{"issue":"5","key":"jrv230009r14","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003044.pub4","article-title":"Non-absorbable disaccharides versus placebo\/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people with cirrhosis.","author":"Gluud","year":"2016","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"jrv230009r15","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.cgh.2015.09.028","article-title":"Efficacy of nutritional therapy for patients with cirrhosis and minimal hepatic encephalopathy in a randomized trial.","volume":"14","author":"Maharshi","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"jrv230009r16","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1136\/gut.2008.176495","article-title":"Combined versus sequential diuretic treatment of ascites in non-azotaemic patients with cirrhosis: results of an open randomised clinical trial.","volume":"59","author":"Angeli","year":"2010","journal-title":"Gut"},{"issue":"3","key":"jrv230009r17","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1053\/jhep.2002.31354","article-title":"Endoscopic treatment versus endoscopic plus pharmacologic treatment for acute variceal bleeding: a meta-analysis.","volume":"35","author":"Ba\u00f1ares","year":"2002","journal-title":"Hepatology"},{"issue":"5","key":"jrv230009r18","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1111\/apt.2011.34.issue-5","article-title":"Meta-analysis: antibiotic prophylaxis for cirrhotic patients with upper gastrointestinal bleeding: an updated Cochrane review.","volume":"34","author":"Chavez-Tapia","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"issue":"25","key":"jrv230009r19","doi-asserted-by":"publisher","first-page":"2370","DOI":"10.1056\/NEJMoa0910102","article-title":"Early use of TIPS in patients with cirrhosis and variceal bleeding.","volume":"362","author":"Garc\u00eda-Pag\u00e1n","year":"2010","journal-title":"N Engl J Med"},{"issue":"6","key":"jrv230009r20","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJM199908053410603","article-title":"Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis.","volume":"341","author":"Sort","year":"1999","journal-title":"N Engl J Med"},{"issue":"9","key":"jrv230009r21","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1056\/NEJMoa2008290","article-title":"Terlipressin plus albumin for the treatment of type 1 hepatorenal syndrome.","volume":"384","author":"Wong","year":"2021","journal-title":"N Engl J Med"},{"issue":"4","key":"jrv230009r22","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/j.jhep.2021.12.022","article-title":"Baveno VII: renewing consensus in portal hypertension.","volume":"76","author":"de Franchis","year":"2022","journal-title":"J Hepatol"},{"issue":"1","key":"jrv230009r23","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1002\/hep.v65.1","article-title":"Portal hypertensive bleeding in cirrhosis: risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the Study of Liver Diseases.","volume":"65","author":"Garcia-Tsao","year":"2017","journal-title":"Hepatology"},{"issue":"10181","key":"jrv230009r24","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1016\/S0140-6736(18)31875-0","article-title":"\u00df Blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial.","volume":"393","author":"Villanueva","year":"2019","journal-title":"Lancet"},{"issue":"6","key":"jrv230009r25","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1002\/hep.29756","article-title":"Patient-reported outcomes in cirrhosis: a scoping review of the literature.","volume":"67","author":"Tapper","year":"2018","journal-title":"Hepatology"},{"issue":"6","key":"jrv230009r26","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1002\/hep4.1512","article-title":"Comprehensive health-state utilities in contemporary patients with cirrhosis.","volume":"4","author":"Foster","year":"2020","journal-title":"Hepatol Commun"},{"issue":"6","key":"jrv230009r27","doi-asserted-by":"publisher","first-page":"895","DOI":"10.14309\/ajg.0000000000001781","article-title":"Pickle Juice Intervention for Cirrhotic Cramps Reduction: the PICCLES randomized controlled trial.","volume":"117","author":"Tapper","year":"2022","journal-title":"Am J Gastroenterol"},{"issue":"7","key":"jrv230009r28","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1111\/apt.14950","article-title":"Randomised clinical trial: oral taurine supplementation versus placebo reduces muscle cramps in patients with chronic liver disease.","volume":"48","author":"Vidot","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"jrv230009r29","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1111\/ajg.2007.102.issue-4","article-title":"Histamine H1 blocker hydroxyzine improves sleep in patients with cirrhosis and minimal hepatic encephalopathy: a randomized controlled pilot trial.","volume":"102","author":"Spahr","year":"2007","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"jrv230009r30","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1002\/hep.30145","article-title":"Primary biliary cholangitis: 2018 practice guidance from the American Association for the Study of Liver Diseases.","volume":"69","author":"Lindor","year":"2019","journal-title":"Hepatology"},{"issue":"4","key":"jrv230009r31","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1053\/gast.1997.v113.pm9322521","article-title":"Oral naltrexone treatment for cholestatic pruritus: a double-blind, placebo-controlled study.","volume":"113","author":"Wolfhagen","year":"1997","journal-title":"Gastroenterology"},{"issue":"4","key":"jrv230009r32","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/0016-5085(83)90130-0","article-title":"Recovery of sexual function in abstinent alcoholic men.","volume":"84","author":"Van Thiel","year":"1983","journal-title":"Gastroenterology"},{"key":"jrv230009r33","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-021-10264-w","article-title":"Tadalafil improves erectile dysfunction and quality of life in men with cirrhosis: a randomized double blind placebo controlled trial.","author":"Jagdish","journal-title":"Hepatol Int"},{"issue":"6","key":"jrv230009r34","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1053\/j.gastro.2015.07.056","article-title":"Trends in burden of cirrhosis and hepatocellular carcinoma by underlying liver disease in US veterans, 2001-2013.","volume":"149","author":"Beste","year":"2015","journal-title":"Gastroenterology"},{"issue":"12","key":"jrv230009r35","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.14309\/ajg.0000000000001909","article-title":"Comorbid chronic diseases and survival in compensated and decompensated cirrhosis: a population-based study.","volume":"117","author":"Asrani","year":"2022","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"jrv230009r36","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/S2468-1253(18)30339-X","article-title":"Incidence of cirrhosis in young birth cohorts in Canada from 1997 to 2016: a retrospective population-based study.","volume":"4","author":"Flemming","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"11","key":"jrv230009r37","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1002\/hep4.1425","article-title":"Incidence of and risk factors for hepatic encephalopathy in a population-based cohort of Americans with cirrhosis.","volume":"3","author":"Tapper","year":"2019","journal-title":"Hepatol Commun"},{"issue":"4","key":"jrv230009r38","doi-asserted-by":"publisher","first-page":"e201997","DOI":"10.1001\/jamanetworkopen.2020.1997","article-title":"Trends in the burden of chronic liver disease among hospitalized US adults.","volume":"3","author":"Hirode","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"1","key":"jrv230009r39","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1038\/s41395-018-0365-4","article-title":"Trends in chronic liver disease-related hospitalizations: a population-based study.","volume":"114","author":"Asrani","year":"2019","journal-title":"Am J Gastroenterol"},{"issue":"9","key":"jrv230009r40","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1016\/j.cgh.2016.04.020","article-title":"Building effective quality improvement programs for liver disease: a systematic review of quality improvement initiatives.","volume":"14","author":"Tapper","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"12","key":"jrv230009r41","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.14309\/ajg.0000000000000762","article-title":"Incidence and bedside predictors of the first episode of overt hepatic encephalopathy in patients with cirrhosis.","volume":"115","author":"Tapper","year":"2020","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"jrv230009r42","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1038\/ajg.2018.6","article-title":"Diagnosis of minimal hepatic encephalopathy: a systematic review of point-of-care diagnostic tests.","volume":"113","author":"Tapper","year":"2018","journal-title":"Am J Gastroenterol"},{"issue":"7","key":"jrv230009r43","doi-asserted-by":"publisher","first-page":"989","DOI":"10.14309\/ajg.0000000000000603","article-title":"Important unresolved questions in the management of hepatic encephalopathy: an ISHEN consensus.","volume":"115","author":"Bajaj","year":"2020","journal-title":"Am J Gastroenterol"},{"issue":"12","key":"jrv230009r44","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1111\/apt.15749","article-title":"Outcomes after hepatic encephalopathy in population-based cohorts of patients with cirrhosis.","volume":"51","author":"Tapper","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"issue":"8","key":"jrv230009r45","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1016\/j.cgh.2016.04.009","article-title":"Rates of and reasons for hospital readmissions in patients with cirrhosis: a multistate population-based cohort study.","volume":"14","author":"Tapper","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"11","key":"jrv230009r46","doi-asserted-by":"publisher","first-page":"5327","DOI":"10.1007\/s10620-022-07454-3","article-title":"Incidence of, risk factors for, and outcomes after ascites in a population-based cohort of older Americans.","volume":"67","author":"Tapper","year":"2022","journal-title":"Dig Dis Sci"},{"issue":"3","key":"jrv230009r47","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/S0168-8278(02)00420-8","article-title":"Incidence and natural history of small esophageal varices in cirrhotic patients.","volume":"38","author":"Merli","year":"2003","journal-title":"J Hepatol"},{"issue":"2","key":"jrv230009r48","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1002\/hep.32737","article-title":"Nonselective beta blockers, hepatic decompensation, and mortality in cirrhosis: a national cohort study.","volume":"77","author":"Serper","year":"2023","journal-title":"Hepatology"},{"issue":"9","key":"jrv230009r49","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1016\/j.cgh.2017.02.018","article-title":"Suboptimal implementation of evidence-based therapy for acute variceal hemorrhage: a systematic review of observational studies.","volume":"15","author":"Tapper","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"32","key":"jrv230009r50","doi-asserted-by":"publisher","first-page":"11326","DOI":"10.3748\/wjg.v20.i32.11326","article-title":"Hospitalization for variceal hemorrhage in an era with more prevalent cirrhosis.","volume":"20","author":"Lim","year":"2014","journal-title":"World J Gastroenterol"},{"issue":"3","key":"jrv230009r51","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1002\/cam4.2019.8.issue-3","article-title":"Real impact of liver cirrhosis on the development of hepatocellular carcinoma in various liver diseases-meta-analytic assessment.","volume":"8","author":"Tarao","year":"2019","journal-title":"Cancer Med"},{"issue":"1","key":"jrv230009r52","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.jhep.2008.07.029","article-title":"The burden of illness associated with hepatocellular carcinoma in the United States.","volume":"50","author":"Lang","year":"2009","journal-title":"J Hepatol"},{"issue":"2","key":"jrv230009r53","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1002\/hep.31884","article-title":"Diagnosis, evaluation, and management of ascites, spontaneous bacterial peritonitis and hepatorenal syndrome: 2021 practice guidance by the American Association for the Study of Liver Diseases.","volume":"74","author":"Biggins","year":"2021","journal-title":"Hepatology"},{"issue":"4","key":"jrv230009r54","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1177\/2050640617744456","article-title":"Microbiology and antibiotic susceptibility patterns in spontaneous bacterial peritonitis.","volume":"6","author":"Oey","year":"2018","journal-title":"United European Gastroenterol J"},{"issue":"2","key":"jrv230009r55","doi-asserted-by":"publisher","first-page":"e68","DOI":"10.1097\/MCG.0000000000000973","article-title":"Trends in hospitalization, acute kidney injury, and mortality in patients with spontaneous bacterial peritonitis.","volume":"53","author":"Devani","year":"2019","journal-title":"J Clin Gastroenterol"},{"issue":"1","key":"jrv230009r56","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/0016-5085(93)90031-7","article-title":"Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites.","volume":"105","author":"Gin\u00e8s","year":"1993","journal-title":"Gastroenterology"},{"issue":"2","key":"jrv230009r57","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.jhep.2021.10.005","article-title":"A genetic risk score and diabetes predict development of alcohol-related cirrhosis in drinkers.","volume":"76","author":"Whitfield","year":"2022","journal-title":"J Hepatol"},{"issue":"1","key":"jrv230009r58","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1002\/hep.31646","article-title":"Vascular liver disorders, portal vein thrombosis, and procedural bleeding in patients with liver disease: 2020 practice guidance by the American Association for the Study of Liver Diseases.","volume":"73","author":"Northup","year":"2021","journal-title":"Hepatology"},{"issue":"5","key":"jrv230009r59","doi-asserted-by":"publisher","first-page":"723","DOI":"10.14309\/ajg.0000000000000343","article-title":"Ammonia levels do not guide clinical management of patients with hepatic encephalopathy caused by cirrhosis.","volume":"115","author":"Haj","year":"2020","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"jrv230009r60","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1002\/hep.30336","article-title":"Frailty, psychoactive medications, and cognitive dysfunction are associated with poor patient-reported outcomes in cirrhosis.","volume":"69","author":"Tapper","year":"2019","journal-title":"Hepatology"},{"issue":"1","key":"jrv230009r61","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1177\/0269216318807051","article-title":"Symptom prevalence and quality of life of patients with end-stage liver disease: a systematic review and meta-analysis.","volume":"33","author":"Peng","year":"2019","journal-title":"Palliat Med"},{"issue":"8","key":"jrv230009r62","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1001\/jama.2012.186","article-title":"Does this patient with liver disease have cirrhosis?","volume":"307","author":"Udell","year":"2012","journal-title":"JAMA"},{"key":"jrv230009r63","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000323","article-title":"AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease.","author":"Rinella","journal-title":"Hepatology"},{"issue":"5","key":"jrv230009r64","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1016\/j.jhep.2021.05.037","article-title":"Prognostic performance of 7 biomarkers compared to liver biopsy in early alcohol-related liver disease.","volume":"75","author":"Rasmussen","year":"2021","journal-title":"J Hepatol"},{"issue":"11","key":"jrv230009r65","doi-asserted-by":"publisher","first-page":"2567","DOI":"10.1016\/j.cgh.2021.12.034","article-title":"Low accuracy of FIB-4 and NAFLD fibrosis scores for screening for liver fibrosis in the population.","volume":"20","author":"Graupera","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"8","key":"jrv230009r66","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1056\/NEJMra1610570","article-title":"Use of liver imaging and biopsy in clinical practice.","volume":"377","author":"Tapper","year":"2017","journal-title":"N Engl J Med"},{"issue":"5","key":"jrv230009r67","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/j.jhep.2020.11.050","article-title":"Refining the Baveno VI elastography criteria for the definition of compensated advanced chronic liver disease.","volume":"74","author":"Papatheodoridi","year":"2021","journal-title":"J Hepatol"},{"issue":"8","key":"jrv230009r68","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1016\/j.cgh.2012.01.015","article-title":"Levels of alanine aminotransferase confound use of transient elastography to diagnose fibrosis in patients with chronic hepatitis C virus infection.","volume":"10","author":"Tapper","year":"2012","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"jrv230009r69","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1053\/j.gastro.2007.05.024","article-title":"Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis.","volume":"133","author":"Ripoll","year":"2007","journal-title":"Gastroenterology"},{"issue":"6","key":"jrv230009r70","doi-asserted-by":"publisher","first-page":"3301","DOI":"10.1002\/hep.32033","article-title":"Test-retest reliability and consistency of HVPG and impact on trial design: a study in 289 patients from 20 randomized controlled trials.","volume":"74","author":"Bai","year":"2021","journal-title":"Hepatology"},{"issue":"6","key":"jrv230009r71","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1002\/hep.28824","article-title":"Noninvasive tools and risk of clinically significant portal hypertension and varices in compensated cirrhosis: the \u201cAnticipate\u201d Study.","volume":"64","author":"Abraldes","year":"2016","journal-title":"Hepatology"},{"issue":"1","key":"jrv230009r72","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1053\/j.gastro.2009.09.007","article-title":"Predicting clinical and histologic outcomes based on standard laboratory tests in advanced chronic hepatitis C.","volume":"138","author":"Ghany","year":"2010","journal-title":"Gastroenterology"},{"issue":"9","key":"jrv230009r73","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.1016\/j.cgh.2019.04.062","article-title":"Performance of Baveno VI and expanded Baveno VI criteria for excluding high-risk varices in patients with chronic liver diseases: a systematic review and meta-analysis.","volume":"17","author":"Stafylidou","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"8","key":"jrv230009r74","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1001\/jama.1982.03320330060027","article-title":"The accuracy of the physical examination in the diagnosis of suspected ascites.","volume":"247","author":"Cattau","year":"1982","journal-title":"JAMA"},{"issue":"10","key":"jrv230009r75","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1001\/jama.299.10.1166","article-title":"Does this patient have bacterial peritonitis or portal hypertension? how do I perform a paracentesis and analyze the results?","volume":"299","author":"Wong","year":"2008","journal-title":"JAMA"},{"issue":"4","key":"jrv230009r76","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1002\/hep.30489","article-title":"Development of quality measures in cirrhosis by the practice metrics committee of the American Association for the Study of Liver Diseases.","volume":"69","author":"Kanwal","year":"2019","journal-title":"Hepatology"},{"issue":"3","key":"jrv230009r77","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1038\/ajg.2010.413","article-title":"Minimal hepatic encephalopathy is associated with falls.","volume":"106","author":"Rom\u00e1n","year":"2011","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"jrv230009r78","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1111\/apt.14824","article-title":"Prospective evaluation of the impact of covert hepatic encephalopathy on quality of life and sleep in cirrhotic patients.","volume":"48","author":"Labenz","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"jrv230009r79","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1002\/hep.29913","article-title":"Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases.","volume":"68","author":"Marrero","year":"2018","journal-title":"Hepatology"},{"issue":"1","key":"jrv230009r80","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.jhep.2022.01.023","article-title":"HCC surveillance improves early detection, curative treatment receipt, and survival in patients with cirrhosis: a meta-analysis.","volume":"77","author":"Singal","year":"2022","journal-title":"J Hepatol"},{"issue":"1","key":"jrv230009r81","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1002\/hep.v48:1","article-title":"Comorbidity and survival of Danish cirrhosis patients: a nationwide population-based cohort study.","volume":"48","author":"Jepsen","year":"2008","journal-title":"Hepatology"},{"issue":"1","key":"jrv230009r82","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.jhep.2005.10.013","article-title":"Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies.","volume":"44","author":"D\u2019Amico","year":"2006","journal-title":"J Hepatol"},{"issue":"15","key":"jrv230009r83","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1056\/NEJM198810133191505","article-title":"Prediction of the first variceal hemorrhage in patients with cirrhosis of the liver and esophageal varices: a prospective multicenter study.","volume":"319","author":"North Italian Endoscopic Club for the Study and Treatment of Esophageal Varices","year":"1988","journal-title":"N Engl J Med"},{"issue":"3","key":"jrv230009r84","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1002\/hep.20339","article-title":"Improved survival after variceal bleeding in patients with cirrhosis over the past two decades.","volume":"40","author":"Carbonell","year":"2004","journal-title":"Hepatology"},{"issue":"4","key":"jrv230009r85","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1002\/hep.23128","article-title":"Minimal hepatic encephalopathy is associated with motor vehicle crashes.","volume":"50","author":"Bajaj","year":"2009","journal-title":"Hepatology"},{"issue":"11","key":"jrv230009r86","doi-asserted-by":"publisher","first-page":"3309","DOI":"10.1007\/s10620-016-4239-6","article-title":"Recalibrating the Child-Turcotte-Pugh score to improve prediction of transplant-free survival in patients with cirrhosis.","volume":"61","author":"Kaplan","year":"2016","journal-title":"Dig Dis Sci"},{"issue":"10","key":"jrv230009r87","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1056\/NEJMoa0801209","article-title":"Hyponatremia and mortality among patients on the liver-transplant waiting list.","volume":"359","author":"Kim","year":"2008","journal-title":"N Engl J Med"},{"issue":"1","key":"jrv230009r88","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1002\/hep.v60.1","article-title":"Survival in infection-related acute-on-chronic liver failure is defined by extrahepatic organ failures.","volume":"60","author":"Bajaj","year":"2014","journal-title":"Hepatology"},{"issue":"11","key":"jrv230009r89","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1111\/apt.2012.35.issue-11","article-title":"Meta-analysis: vasoactive medications for the management of acute variceal bleeds.","volume":"35","author":"Wells","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"jrv230009r90","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1046\/j.1365-2036.2003.01356.x","article-title":"Systematic review: terlipressin in acute oesophageal variceal haemorrhage.","volume":"17","author":"Ioannou","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"jrv230009r91","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1002\/hep.27941","article-title":"The empirical antibiotic treatment of nosocomial spontaneous bacterial peritonitis: results of a randomized, controlled clinical trial.","volume":"63","author":"Piano","year":"2016","journal-title":"Hepatology"},{"issue":"9","key":"jrv230009r92","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1056\/NEJMoa2022166","article-title":"A randomized trial of albumin infusions in hospitalized patients with cirrhosis.","volume":"384","author":"China","year":"2021","journal-title":"N Engl J Med"},{"issue":"6","key":"jrv230009r93","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1016\/j.jhep.2012.01.012","article-title":"Noradrenaline vs terlipressin in the treatment of hepatorenal syndrome: a randomized study.","volume":"56","author":"Singh","year":"2012","journal-title":"J Hepatol"},{"issue":"8","key":"jrv230009r94","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1002\/lt.26065","article-title":"Feasibility and effectiveness of norepinephrine outside the intensive care setting for treatment of hepatorenal syndrome.","volume":"27","author":"Kwong","year":"2021","journal-title":"Liver Transpl"},{"issue":"5","key":"jrv230009r95","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1002\/hep.29557","article-title":"Portal pressure and liver stiffness measurements in the prediction of fibrosis regression after sustained virological response in recurrent hepatitis C.","volume":"67","author":"Mauro","year":"2018","journal-title":"Hepatology"},{"issue":"9865","key":"jrv230009r96","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/S0140-6736(12)61425-1","article-title":"Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study.","volume":"381","author":"Marcellin","year":"2013","journal-title":"Lancet"},{"issue":"2","key":"jrv230009r97","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1001\/jama.2021.7683","article-title":"Diagnosis and treatment of alcohol-associated liver disease: a review.","volume":"326","author":"Singal","year":"2021","journal-title":"JAMA"},{"issue":"6","key":"jrv230009r98","doi-asserted-by":"publisher","first-page":"2080","DOI":"10.1002\/hep.31042","article-title":"Impact of alcohol use disorder treatment on clinical outcomes among patients with cirrhosis.","volume":"71","author":"Rogal","year":"2020","journal-title":"Hepatology"},{"issue":"5","key":"jrv230009r99","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1007\/s11695-021-05289-x","article-title":"Outcomes of bariatric surgery in patients with liver cirrhosis: a systematic review.","volume":"31","author":"Ahmed","year":"2021","journal-title":"Obes Surg"},{"issue":"1","key":"jrv230009r100","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1002\/hep.28535","article-title":"Risk of hepatocellular carcinoma after sustained virological response in veterans with hepatitis C virus infection.","volume":"64","author":"El-Serag","year":"2016","journal-title":"Hepatology"},{"issue":"9","key":"jrv230009r101","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1111\/apt.15499","article-title":"Tenofovir disoproxil fumarate reduces hepatocellular carcinoma, decompensation and death in chronic hepatitis B patients with cirrhosis.","volume":"50","author":"Liu","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"jrv230009r102","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/S2468-1253(16)30024-3","article-title":"Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.","volume":"1","author":"Chan","year":"2016","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"2","key":"jrv230009r103","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1097\/QAI.0000000000001350","article-title":"Brief report: randomized, double-blind comparison of tenofovir alafenamide (TAF) vs tenofovir disoproxil fumarate (TDF), each coformulated with elvitegravir, cobicistat, and emtricitabine (E\/C\/F) for initial HIV-1 treatment: week 144 results.","volume":"75","author":"Arribas","year":"2017","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"2","key":"jrv230009r104","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1097\/00004836-200308000-00018","article-title":"Treatment with ursodeoxycholic acid is associated with weight gain in patients with primary biliary cirrhosis.","volume":"37","author":"Siegel","year":"2003","journal-title":"J Clin Gastroenterol"},{"issue":"3","key":"jrv230009r105","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1002\/hep.23045","article-title":"Randomized controlled trial of carvedilol versus variceal band ligation for the prevention of the first variceal bleed.","volume":"50","author":"Tripathi","year":"2009","journal-title":"Hepatology"},{"issue":"14","key":"jrv230009r106","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1056\/NEJMoa1912484","article-title":"Timing of endoscopy for acute upper gastrointestinal bleeding.","volume":"382","author":"Lau","year":"2020","journal-title":"N Engl J Med"},{"issue":"3","key":"jrv230009r107","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1111\/j.1600-0676.1993.tb00624.x","article-title":"Efficacy and safety of the stepped care medical treatment of ascites in liver cirrhosis: a randomized controlled clinical trial comparing two diets with different sodium content.","volume":"13","author":"Bernardi","year":"1993","journal-title":"Liver"},{"issue":"3","key":"jrv230009r108","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1053\/j.gastro.2007.06.020","article-title":"Transjugular intrahepatic portosystemic shunt for refractory ascites: a meta-analysis of individual patient data.","volume":"133","author":"Salerno","year":"2007","journal-title":"Gastroenterology"},{"issue":"8","key":"jrv230009r109","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1016\/j.cgh.2021.07.018","article-title":"North American practice-based recommendations for transjugular intrahepatic portosystemic shunts in portal hypertension.","volume":"20","author":"Boike","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"10138","key":"jrv230009r110","doi-asserted-by":"publisher","first-page":"2417","DOI":"10.1016\/S0140-6736(18)30840-7","article-title":"Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial.","volume":"391","author":"Caraceni","year":"2018","journal-title":"Lancet"},{"issue":"5","key":"jrv230009r111","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1007\/s10620-019-05858-2","article-title":"Limited progress in hepatorenal syndrome (HRS) reversal and survival 2002-2018: a systematic review and meta-analysis.","volume":"65","author":"Thomson","year":"2020","journal-title":"Dig Dis Sci"},{"issue":"8","key":"jrv230009r112","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1016\/j.jvir.2019.04.017","article-title":"Society of Interventional Radiology consensus guidelines for the periprocedural management of thrombotic and bleeding risk in patients undergoing percutaneous image-guided interventions-part II: recommendations: endorsed by the Canadian Association for Interventional Radiology and the Cardiovascular and Interventional Radiological Society of Europe.","volume":"30","author":"Patel","year":"2019","journal-title":"J Vasc Interv Radiol"},{"issue":"2","key":"jrv230009r113","doi-asserted-by":"publisher","first-page":"284","DOI":"10.14309\/ajg.0000000000002008","article-title":"Systematic review and meta-analysis on the effects of lactulose and rifaximin on patient-reported outcomes in hepatic encephalopathy.","volume":"118","author":"Moon","year":"2023","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"jrv230009r114","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1002\/hep.v48:2","article-title":"Nocturnal nutritional supplementation improves total body protein status of patients with liver cirrhosis: a randomized 12-month trial.","volume":"48","author":"Plank","year":"2008","journal-title":"Hepatology"},{"issue":"3","key":"jrv230009r115","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1002\/hep.32049","article-title":"Malnutrition, frailty, and sarcopenia in patients with cirrhosis: 2021 practice guidance by the American Association for the Study of Liver Diseases.","volume":"74","author":"Lai","year":"2021","journal-title":"Hepatology"},{"key":"jrv230009r3","unstructured":"Centers for Disease Control and Prevention. CDC WONDER: about provisional mortality statistics, 2018 through last month. Accessed March 13, 2023. https:\/\/wonder.cdc.gov\/mcd-icd10-provisional.html"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2804599\/jama_tapper_2023_rv_230009_1682950994.35318.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,9]],"date-time":"2023-05-09T18:30:42Z","timestamp":1683657042000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2804599"}},"subtitle":["A Review"],"short-title":[],"issued":{"date-parts":[[2023,5,9]]},"references-count":115,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2023,5,9]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2023.5997","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5,9]]}}}